Companies in #Immuno-Oncology

ALX Oncology Holdings is a clinical-stage biotechnology company based in South San Francisco that engineers therapies designed to help the immune system fight cancer. Its lead asset, evorpacept, is a CD47-blocking fusion protein pairing a high-affinity SIRPalpha domain with an inactive Fc region, developed to relieve the 'don't eat me' signal that tumour cells use to evade macrophage clearance and to be combined with antibody-based regimens. The company is running biomarker-selected mid-stage programmes in HER2-positive gastric and gastroesophageal junction cancer and HER2-positive breast cancer, and is advancing ALX2004, an EGFR-targeted antibody-drug conjugate, in EGFR-expressing solid tumours. ALX Oncology has no approved products or product revenue and funds operations from its cash balance and public equity markets; it has traded on the Nasdaq Global Select Market under the ticker ALXO since its 2020 initial public offering and closed below $1.00 for the first time on October 13, 2026, versus a 52-week range of $1.05 to $2.66.

BioAtla is a clinical-stage biopharmaceutical company developing novel antibody and cell-based therapeutics for solid tumors using its proprietary Conditionally Active Biologics (CAB) platform, which exploits the tumor microenvironment to improve therapeutic index. Lead programs include mecbotamab vedotin (BA3011), a CAB-AXL antibody-drug conjugate (ADC) in clinical development for undifferentiated pleomorphic sarcoma and non-small cell lung cancer, and ozuriftamab vedotin (CAB-ROR2-ADC), targeting ROR2-expressing tumors. The company initiated a strategic review in March 2026; in August 2026 the Nasdaq Listing Council affirmed a delisting determination and the common stock is expected to transition to OTC Markets trading effective August 31, 2026.

Clinical-stage biopharmaceutical company using AI to identify and develop novel therapies in neuroscience and immuno-oncology. Filed for bankruptcy in August 2026 and agreed to sell assets to Teva Pharmaceutical for up to $125M.

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company that designs immune-stimulating antibody conjugates (ISACs) — tumour-targeting antibodies linked to TLR7/8 agonist payloads that activate myeloid cells inside the tumour microenvironment. Its Boltbody platform generated BDC-4182, a claudin 18.2-directed ISAC in Phase 1/2, while most of the earlier pipeline was placed on hold during a 2025 restructuring. In October 2026 the company acquired Prana Therapies in a stock-for-stock reverse merger alongside a $120 million private placement, refocusing the enterprise on PRA-216 in inflammatory disease.

Clinical-stage biotechnology company developing first-in-class oral small molecules and immunotherapies to reprogram immune signaling pathways in oncology and autoimmune diseases.

Clinical-stage biotechnology company developing RNA-based immune activators that turn cold tumors hot, led by intralesional BO-112 for skin tumors and other solid tumors.

Immutep Limited is a globally operating clinical-stage biotechnology company developing novel LAG-3 (Lymphocyte Activation Gene-3) immunotherapies for cancer and autoimmune diseases. Headquartered in Sydney, Australia, with major operational and clinical research facilities in Châtenay-Malabry (Paris), France, and Berlin, Germany, the company was built around the foundational LAG-3 discoveries of CSO Dr. Frédéric Triebel. Its lead oncology asset, eftilagimod alfa (efti), is a first-in-class soluble LAG-3 fusion protein acting as an antigen-presenting cell activator targeting MHC Class II, evaluated in combination with checkpoint inhibitors across solid tumors. Following an independent data monitoring committee futility finding for the registrational Phase 3 TACTI-004 trial in 1L non-small cell lung cancer in 2026, Immutep initiated targeted workforce downsizing and trial wind-down to preserve capital and extend its cash runway into 2028 while advancing IMP761, a first-in-class LAG-3 agonist antibody in Phase 1 trials for autoimmune diseases.

Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies and vaccines based on two non-viral delivery platforms, TheraPlas for coding proteins and cytokines and PlaCCine for coding viral antigens. Its lead programme is IMNN-001, a DNA-based immunotherapy encoding interleukin-12 that is in a Phase 3 trial for the localised treatment of advanced ovarian cancer, with IND-enabling work in colorectal and pancreatic cancer and discovery work in glioblastoma. A second programme, IMNN-101, is a COVID-19 booster vaccine that has completed Phase 1. The company was incorporated in 1982, was formerly known as Celsion Corporation, and took its current name in September 2022; it is headquartered in Lawrenceville, New Jersey and employs roughly 20 people. In September 2026 Imunon converted $1.2 million of debt to equity, lowering the outstanding balance of the original note by about 43% without issuing common stock or dilutive warrants.

Nouscom is a clinical-stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines on a proprietary viral-vector platform, including the NOUS-209 program in Lynch syndrome and neoantigen vaccines encoding hundreds of tumor-specific antigens. It operates from Basel, Switzerland and Rome, Italy.

Commercial-stage biopharmaceutical company developing gene and cell therapies for difficult-to-treat diseases, with a focus on immuno-oncology and precision medicine; its AdenoVerse immunotherapeutic platform received FDA platform technology designation in September 2026.

Pyxis Oncology is a clinical-stage company developing next-generation antibody-drug conjugates and immunotherapies for difficult-to-treat solid tumors. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an antibody-drug conjugate that targets extradomain-B fibronectin, a structural component of the tumor extracellular matrix rather than a surface antigen on the cancer cell itself; it holds FDA Fast Track designation and is being evaluated in Phase 1 monotherapy cohorts and in a Phase 1/2 combination study with Merck's pembrolizumab, with recurrent and metastatic head and neck squamous cell carcinoma the focus indication. A portfolio prioritization narrowed development onto that lead program. Founded in 2018 as a spinout of Longwood Fund with an early licensing relationship with Pfizer, and headquartered in Boston, Massachusetts, the company went public on Nasdaq in October 2021. It remains pre-revenue and funds development from the balance sheet: on September 30, 2026 it priced a registered public offering of 36,047,919 common shares, or pre-funded warrants in lieu, paired with warrants for expected gross proceeds of approximately $110 million and up to $282.6 million if the accompanying warrants are exercised in full.

Shattuck Labs is a clinical-stage biotechnology company developing novel biotherapeutics based on its proprietary Agonist Redirected Checkpoint (ARC) platform, which combines elements of antibody and cytokine receptor signaling in single fusion proteins for the treatment of cancer and inflammatory disease.

Zymeworks is a clinical-stage biotechnology company developing multifunctional biotherapeutics for difficult-to-treat cancers. The company's platforms include Azymetric (bispecific antibodies) and EFECT (immune-effector modulation), and it is advancing multiple wholly-owned and partnered oncology candidates. In 2026 Zymeworks expanded its pipeline through the near-$1B acquisition of Theravance Biopharma, adding a lung-disease drug candidate plus royalty streams.